Organon & Co. (NYSE:OGN) Hits New 12-Month Low – Time to Sell?

Organon & Co. (NYSE:OGN) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $10.89 and last traded at $10.93, with a volume of 294850 shares. The stock had previously closed at $11.05.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OGN. Morgan Stanley cut their price objective on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 9th. TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.60.

Organon & Co. Price Performance

The firm has a market cap of $2.85 billion, a P/E ratio of 3.32, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The stock’s 50-day moving average is $14.48 and its 200-day moving average is $15.56. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.12%. Organon & Co.’s dividend payout ratio is currently 33.63%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OGN. Pacer Advisors Inc. increased its holdings in Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after buying an additional 11,140,388 shares during the period. Norges Bank bought a new stake in Organon & Co. in the fourth quarter valued at about $25,258,000. Magnetar Financial LLC raised its position in Organon & Co. by 560.2% in the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company’s stock worth $25,878,000 after purchasing an additional 1,471,731 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Organon & Co. during the fourth quarter worth about $11,892,000. Finally, Dimensional Fund Advisors LP lifted its stake in Organon & Co. by 23.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company’s stock worth $48,999,000 after purchasing an additional 629,191 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.